Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1006959
Abstract: Dedifferentiated liposarcoma (DDLPS) is an aggressive adipogenic cancer with poor prognosis. DDLPS tumors are only modestly sensitive to chemotherapy and radiation, and there is a need for more effective therapies. Genetically, DDLPS is characterized by… read more here.
Keywords: mdm2; p53 pathway; dedifferentiated liposarcoma; p53 ... See more keywords